1. Kuongororwa uye kurapwa kwekutanga kwekenza yemapapu
Murwere Lu akaonekwa kuti ane lung adenocarcinoma uye lymph node metastasis musi waAugust 26, 2005. Rudzi rwekuruboshwe rworuboshwe rwakaitwa musi waSeptember 22, 2005. Carboplatin yakasanganiswa netaxotere yakashandiswa 4 nguva mushure mekuvhiyiwa. Musi waNyamavhuvhu 3, 2007, nekuda kwekuputika kwepleural, kuongororwa kwakasimbiswa kuve kwakadzokororwa, uye akarapwa neTarceva (nhamba yemakonzo haizivikanwe). Musi wa8 Ndira 2008, kufambira mberi kwegomarara kwakawanikwa pakuongororwazve, uye kurapwa kweTarceva kwakamiswa uye kurapwa kweLibita kwakatangwa kwegumi nematanhatu. Panguva imwecheteyo, vertebral hip metastasis yakawanikwa uye 16 maitiro eZetai akaitwa.
2. Nguva yekutanga kutora chikamu mumakiriniki ekuedzwa, mamiriro acho ari pasi pekutonga.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumarara was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Muchiitiko chechipiri chekliniki, bundu rakanyangarika zviri pachena.
On August 6, 2012, Mr. Lu participated in the AP26113 drug kliniki yekuedzwa at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the bundu muuropi decreased and became large.
4. Ziva zvisingawanzo gadziriso dzemajini uye tarisira kutora chikamu muzviedzo zvitsva zvekiriniki
Kuongororazve muna Chikunguru 2014, muviri wose PET wakaratidza: Zvironda zvehuropi zvaive zvakagadzikana, uye chifuva chaiva nekufambira mberi kwakajeka. Musi waChivabvu 12, 2014, aifungidzirwa kuti anorwisa-AP26113 lymph (masero matatu, makuru 3 cm) akagadzirwa mumutsara wemasero akaitwa paMassachusetts General Hospital uye akaramba achitora AP1.1.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
